Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ) was Initiated by Goldman to “Buy” and the brokerage firm has set the Price Target at $196. Goldman advised their investors in a research report released on Jun 6, 2016.
Many Wall Street Analysts have commented on Jazz Pharmaceuticals plc – Ordinary Shares. Company shares were Upgraded by Mizuho on May 11, 2016 to ” Buy”, Firm has raised the Price Target to $ 193 from a previous price target of $137 .Company shares were Reiterated by UBS on May 11, 2016 to “Buy”, Firm has raised the Price Target to $ 168 from a previous price target of $162 .Jazz Pharmaceuticals plc – Ordinary Shares was Upgraded by Sun Trust Rbsn Humphrey to ” Buy” on Apr 25, 2016.
On the company’s financial health, Jazz Pharmaceuticals plc – Ordinary Shares reported $2.26 EPS for the quarter, missing the analyst consensus estimate by $ -0.06 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $2.32. The company had revenue of $336.01 million for the quarter, compared to analysts expectations of $340.17 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.
Jazz Pharmaceuticals plc – Ordinary Shares closed down -3.24 points or -2.08% at $152.75 with 5,27,253 shares getting traded on Friday. Post opening the session at $154.72, the shares hit an intraday low of $150.3 and an intraday high of $154.72 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on May 26, 2016, Seamus Mulligan (director) sold 27,968 shares at $150.13 per share price. According to the SEC, on May 17, 2016, Michael Patrick Miller (SVP, US Commercial) sold 100 shares at $145.20 per share price. On May 17, 2016, Heather Ann Mcsharry (director) sold 697 shares at $145.20 per share price, according to the Form-4 filing with the securities and exchange commission.